v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 28,719 $ 37,189
Research and development related success payments and contingent consideration 8,433 1,957
General and administrative 11,462 11,484
Total operating expenses 48,614 50,630
Loss from operations (48,614) (50,630)
Interest income, net 951 992
Other income, net 453 249
Net loss $ (47,210) $ (49,389)
Net loss per common share - basic $ (0.17) $ (0.21)
Net loss per common share - diluted $ (0.17) $ (0.21)
Weighted-average number of common shares - basic 276,856 237,578
Weighted-average number of common shares - diluted 276,856 237,578